Literature DB >> 24742610

Cavitary pulmonary disease in a patient treated with natalizumab.

Adèle de Masson1, Elisabeth Maillart2, Nicolas Veziris3, Vanina Meyssonnier1, Caroline Papeix2, Eric Caumes4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24742610     DOI: 10.1016/j.lpm.2013.12.012

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


× No keyword cloud information.
  5 in total

Review 1.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

2.  A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients.

Authors:  Agnese Gugliandolo; Federica Longo; Maria Giovanna Marrosu; Giovanni Luigi Mancardi; Ilaria Gandoglia; Maurizio Melis; Fabrizio Lo Giudice; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2018-09-26       Impact factor: 2.423

3.  Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review.

Authors:  Yuichiro Yasuda; Tatsuya Nagano; Motoko Tachihara; Norio Chihara; Kanoko Umezawa; Naoko Katsurada; Masatsugu Yamamoto; Kenji Sekiguchi; Kazuyuki Kobayashi; Yoshihiro Nishimura
Journal:  Ther Clin Risk Manag       Date:  2019-11-01       Impact factor: 2.423

Review 4.  '"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection.

Authors:  M Alexandra Lake; Lyn R Ambrose; Marc C I Lipman; David M Lowe
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

5.  Pulmonary eosinophilia associated to treatment with natalizumab.

Authors:  Elena Curto; Elvira Munteis-Olivas; Eva Balcells; M Marisol Domínguez-Álvarez
Journal:  Ann Thorac Med       Date:  2016 Jul-Sep       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.